Boothbay Fund Management’s Capricor Therapeutics CAPR Stock Holding History

Boothbay Fund Management’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.65M	Buy	192,962 +16,817	+10%	+$510K	0.06%	378
2026 Q1	$5.35M	Sell	176,145 -14,585	-8%	-$389K	0.07%	303
2025 Q4	$5.5M	Buy	190,730 +86,993	+84%	+$1.14M	0.08%	265
2025 Q3	$748K	Buy	+103,737	New	+$764K	0.01%	963
2024 Q4	–	Sell	-87,750	Closed	-$1.54M	–	1528
2024 Q3	$1.33M	Buy	+87,750	New	+$434K	0.03%	661

Other funds holding CAPR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boothbay Fund Management's CAPR Position: Q2 2026 in Review

Boothbay Fund Management increased its Capricor Therapeutics (CAPR) stake by 9.5% in Q2 2026, buying an estimated $510K and bringing the position to 192,962 shares worth $4.65M. The position accounts for 0.06% of the portfolio, ranked #378.

Boothbay Fund Management first reported a position in CAPR in Q3 2024 and has held it in 5 quarters since. The position peaked at $5.5M in Q4 2025. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

Boothbay Fund Management held 192,962 shares of Capricor Therapeutics worth $4.65M as of Q2 2026.
Boothbay Fund Management bought 16,817 Capricor Therapeutics shares in Q2 2026, an estimated $510K.
Capricor Therapeutics made up 0.06% of Boothbay Fund Management's portfolio in Q2 2026, its #378 holding.
Boothbay Fund Management first reported a position in Capricor Therapeutics in Q3 2024 and has held it in 5 quarters since.
Boothbay Fund Management's Capricor Therapeutics position peaked at $5.5M in Q4 2025.
169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.